These courses are intended for internal hospital staff.

Activity Description:

The Hematology Conference offers an opportunity to focus on patient cases and align on treatment strategies across disciplines for ideal patient care and/or the review of treatment strategies based on outcomes. Based on the discussion around treatment strategies, new medical knowledge will ideally be addressed and application per patient case evaluated. During each session in this series, attendees will participate in a multidisciplinary team discussion of both prospective and follow-up case presentations. This tumor board series will address the patient care process, including diagnosis and diagnostic criteria, treatment, treatment options, and post-treatment follow-up.

Target Audience:

Specialties - Hematology/Oncology, Oncology, Pathology

Learning Objective:

At the conclusion of this course, learners should be able to:

• Implement optimal course of treatment for breast cancer patients.
• Utilize multiple disciplinary approaches to diagnosis and treatment options, including radiological findings, pathological findings and immunohistochemical testing. 
• Determine cancer staging using various breast imaging modalities.
• Promote a multidisciplinary team approach by bridging gaps across the continuum of care in order to enhance the overall quality of patient-centered cancer care.

Moderator:

Jeff Matous, MD

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

Accreditation:

The HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Credit Designation:

The HCA Healthcare Continental Division designates this live activity for a maximum of 1.0 AMA PRA Category 1^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:  

This Activity was developed without support from any ineligible company.*The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.

Disclosure: 

The HCA Healthcare Continental Division is committed to providing CME that is balanced, objective, and evidenced-based. In accordance with the Accreditation Council for Continuing Medical Education Standards for Integrity and Independence all parties involved in content development are required to disclose all conflicts of interest with ACCME defined ineligible companies. The HCA Healthcare Continental Division has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. The CME planning committee who are in a position to control the content of this CME Activity, have no relevant financial relationships with ineligible companies to disclose.